Insys Therapeutics, Inc. (INSY) Under Analyst Spotlight - UK Market News

Amid volatile financial markets and the presidential election, various investment brokerages have made amendments to their price targets and ratings on shares of Insys Therapeutics, Inc. (INSY). Based on the latest brokerage notes which have been ...

Investors Are Circling INSYS Therapeutics, Inc. (NasdaqGM:INSY), How Does the Market Value the Shares? - Financial Newsweek

The Price to Book ratio for INSYS Therapeutics, Inc. NasdaqGM:INSY is 2.412496. The Price to book ratio is the current share price of a company divided by the book value per share. A lower price to book ratio indicates that the stock might be undervalued.

Bargain or Bust? What's beyond the Numbers For Cardiome Pharma Corp. (TSX:COM) - Financial Newsweek

The Price to book ratio is the current share price of a company divided by the book value per share. The Price to Book ratio for Cardiome Pharma Corp. TSX:COM is 2.414498. A lower price to book ratio indicates that the stock might be undervalued ...

Subsys maker blames former workers for 'inappropriate actions' - Cherry Hill Courier Post

TRENTON – A pharmaceutical firm, accused of mounting a “greed-driven scheme” to promote the misuse of an opioid-fentanyl drug, on Friday acknowledged the “inappropriate actions taken by some of our former employees.” Insys Therapeutics, which was ...

INSYS Therapeutics, Inc. (NasdaqGM:INSY) Value Composite Rank in The Spotlight - Financial Newsweek

The Value Composite Two of INSYS Therapeutics, Inc. (NasdaqGM:INSY) is 70. The VC2 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, price to earnings and shareholder yield. Similarly, the Value Composite ...

Insys Therapeutics Inc. (INSY) Moves Lower on Volume Spike for October 06 - Equities.com

Insys Therapeutics Inc. (INSY) traded on unusually high volume on Oct. 06, as the stock lost 2.74% to close at $8.86. On the day, Insys Therapeutics Inc. saw 845,769 shares trade hands on 4,347 trades. Considering that the stock averages only a daily ...

Attorney General: Drug Company 'Nothing Short Of Evil' - Western Journalism

Officials in New Jersey are suing a major pharmaceutical company over their alleged role in igniting the addiction epidemic through deceptive marketing and fraudulent payouts. New Jersey Attorney General Christopher Porrino filed a lawsuit Thursday ...

Somewhat Favorable News Coverage Somewhat Unlikely to Impact Insys Therapeutics (INSY) Share Price - The Ledger Gazette

Insys Therapeutics logo News articles about Insys Therapeutics (NASDAQ:INSY) have been trending somewhat positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than twenty ...

Insys hit with lawsuit, fine for opioid marketing - BioPharma Dive

New Jersey is the latest state to bring charges against opioid drugmaker Insys Therapeutics Inc., charging the biotech conducted a "greed-driven campaign of consumer fraud and submission of false claims to health insurers" to promote its drug Subsys.

New Jersey sues painkiller company, calling its methods “evil” - The Cannabist

TRENTON, N.J. — A drug company that makes a powerful fentanyl painkiller spray has engaged in conduct that is “nothing short of evil,” New Jersey's attorney general Christopher S. Porrino said Thursday after the state became the latest to file a ...

INSYS Therapeutics, Inc. (INSY) stands -4.47% away from 50 SMA: Technical Watch - Voice Of Analysts

INSYS Therapeutics, Inc. (INSY) added with positive flow of 3.05% during recent week and go down so far this year; showing a decline of -0.98%. The shares price has directed -29.87% toward a lower level throughout last year and swapped -3.09% toward a ...

INSYS Therapeutics, Inc. (INSY) stock lost -30.14% Quarterly return - Street Observer (press release)

INSYS Therapeutics, Inc. (INSY) stock price is moving downswing along with the volume 1.01 million shares in recent session. Shares are clocking price at $9.11 with change of -2.46%. The company's 3-months average volume stands at 0.56 million.

Broker Outlook For The Week Ahead Insys Therapeutics, Inc. (INSY) - Fiscal Standard

Currently 6 analysts have outstanding research reports on Insys Therapeutics, Inc. (INSY), according to the reports 2 analysts rate the stock “Buy”, 2 “Outperform”, 0 “Underperform”, 0 “Sell”, while 2 “Hold”. The most recently updated ratings and price ...

What We're Reading: Insys Opioid Lawsuits; Birth Control Mandate; Uninsured Virginians - AJMC.com Managed Markets Network

Massachusetts reaching a settlement with Insys Therapeutics over the company's marketing of its opioid, Subsys, may have opened the door to more lawsuits. According to The Wall Street Journal, New Jersey has now filed a lawsuit against Insys claiming ...

A Few Clear Signs For INSYS Therapeutics, Inc. (INSY), Wayfair Inc. (W) - AllStockNews

INSYS Therapeutics, Inc. (NASDAQ:INSY) trades at $9.11 having a market capitalization of $659.2 million. INSY stock price lost -29.87% over the past year, yielding a negative weighted alpha of -31.4 percent. A weighted alpha below 0 suggest additional ...

New Jersey sues drugmaker Insys over opioid analgesic - Pharmacy Today, American Pharmacists Association, pharmacist.com

New Jersey Attorney General Christopher Porrino has filed a lawsuit against Insys Therapeutics, alleging the company fraudulently marketed its fentanyl sublingual spray (Subsys) for widespread use, despite having only received FDA approval to treat ...

INSYS Therapeutics Addresses New Jersey Complaint - Nasdaq

PHOENIX, Oct. 06, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) ("INSYS" or "the Company") today released the following statement: We would like to reiterate that we continue to work with relevant authorities to resolve issues ...

Volunteers to raise awareness about opioid abuse - Philly.com

TRENTON, N.J. (AP) - Some 2,000 volunteers across New Jersey are fanning out to raise awareness about opioid abuse. Friday is Knock Out Opioid Abuse Day. The Partnership for a Drug-Free New Jersey and other community groups are distributing ...

Equity Research Analyst's Stock Ratings: INSYS Therapeutics, Inc. (INSY), Windstream Holdings, Inc. (WIN) - Analyst Journal

INSYS Therapeutics, Inc. (NASDAQ:INSY) tinted loss of -2.46% (-0.23 points) to US$9.11. The volume of 1 Million shares climbed down over an trading activity of 547.69 Million shares. EPS ratio determined by looking at last 12 month figures is -0.21 ...

NJ Politics Digest: NJ Sues Drug Company Over 'Evil' Sales Scheme - Observer

New Jersey Attorney General Christopher Porrino accused a drug company of an “evil” scheme to boost sales of a fentanyl painkiller after the state filed a lawsuit Thursday against the firm, according to reports. The state's lawsuit alleges that Insys ...